Tocilizumab was safe and effective for RA patients in comparison to tocilizumab plus DMARD therapy.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
October 28, 2014 2:46 AM
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyVijay U. Rao MD, PhD1,†, Andrey Pavlov PhD2, Micki Klearman MD1,*, David Musselman MD1, Jon T. Giles MD, MPH3,Joan M. Bathon MD3, Naveed Sattar FRCPath, PhD4 andJanet S. Lee PhD5,‡
DOI: 10.1002/art.38920 Copyright © 2014 American College of Rheumatology Issue Arthritis & RheumatologyAccepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) |
Krishan Maggon 's curator insight,
March 23, 2015 8:08 AM
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry Ryoko Sakai†, Soo-Kyung Cho†, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka, Masayoshi Harigai* and for the REAL Study Group *Corresponding author: Masayoshi Harigai mharigai.mpha@tmd.ac.jp † Equal contributors Author Affiliations For all author emails, please log on. Arthritis Research & Therapy 2015, 17:74 doi:10.1186/s13075-015-0583-8
Ryoko Sakai and Soo-Kyung Cho contributed equally to this work. Published: 23 March 2015
Krishan Maggon 's curator insight,
August 8, 2014 7:03 PM
open access full text
RA patients not responding to TNF inhibitors benefit from treatment with IL6 targeting mabs and show regression of RA disease.
Ann Rheum Dis 2014;73:1595-1597 doi:10.1136/annrheumdis-2013-205002 EditorialIL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumabYoshiya Tanaka1, Emilio Martin Mola2+Author Affiliations 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan2Servicio de Reumatología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, Madrid, SpainCorrespondence toProfessor Yoshiya Tanaka, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, Japan; tanaka@med.uoeh-u.ac.jpReceived 31 January 2014Revised 23 April 2014Accepted 1 May 2014Published Online First 15 May 2014 |
Clinical Rheumatology